Program
Preliminary program
| DAY 1, February 13, 2025 | |||
| 18:00 | Round table discussion |
Closed session
|
|
| DAY 2, February 14, 2025 | |||
| Session I Chairs: Monika Holubová (Charles University, Czech Republic), Dominik Schneidawind (University Hospital Zurich, Switzerland) |
|||
| 08:30 | Welcome |
Monika Holubová
Charles University, Czech RepublicCiRT co-founder |
|
| 08:45 | Opening remarks |
Antonia Rotolo
University of Pennsylvania, United StatesCiRT co-founder |
|
| 09:00 | Keynote lecture |
Giulia Casorati
San Raffaele Scientific Institute, Italy
|
Harnessing the iNKT cell platform for adoptive immunotherapy of cancer
|
| 09:30 | Short talk |
Melissa Mavers
Washington University School of Medicine, United States
|
Diversity in human iNKT cells across immunologically relevant hematologic tissues
|
| 09:45 | Short talk |
Mads Clausen
Technical University of Denmark, Denmark
|
Alpha-galactosyl ceramide as adjuvant in vaccines for cancer and infectious disease
|
| 10:00 | Sponsor presentation |
Biovendor/Sartorius
|
|
| 10:10 | Coffee break | ||
| Session II Chairs: Mark Exley (MiNK Therapeutics Inc., United States), Gloria Delfanti (San Raffaele Scientific Institute, Italy) |
|||
| 10:40 | Keynote lecture |
Dominik Schneidawind
University Hospital Zurich, Switzerland
|
TBS
|
| 11:10 | Keynote lecture |
Jenny Gumperz
University of Wisconsin School of Medicine and Public Health, United States
|
iNKT cell immunotherapy to improve hematopoietic transplantation
|
| 11:40 | Short talk |
Tonya Webb
Washington University in St. Louis School of Medicine, United States
|
Modulating lipid metabolism to enhance antitumor NKT cell responses
|
| 11:55 | Short talk |
Lilin Zhang
BrightPath Biotherapeutics Co., Ltd., Japan
|
iPSC-derived HER2 CAR-iNKT cells boost anti-tumor activity of CTLs in a tumor xenograft mouse model
|
| 12:10 | Sponsor presentation |
Exbio
|
|
| 12:20 | Lunch | ||
| Session III Chairs: Francesco Strati (University of Milano-Bicocca, Italy), Mariolina Salio (Immunocore LTD, United Kingdom) |
|||
| 13:20 | Keynote lecture |
Leonid Metelitsa
Baylor College of Medicine, United States
|
Developing CAR-NKT Cancer Immunotherapy: Leveraging NKT Cell Biology and Advancements in CAR Design
|
| 13:50 | Keynote lecture |
Mark Exley
MiNK Therapeutics Inc., United States
|
Getting iNKT cells 'back' to the patient
|
| 14:20 | Short talk |
Fátima Macedo
University of Algarve, Portugal
|
Human iNKT cells induce activation and subset-dependent cell death of macrophages
|
| 14:35 | Short talk |
Robson Dossa
Arovella Therapeutics, Australia
|
Development of CAR-iNKT cells for the treatment and haematological malignancies and solid tumours
|
| 14:50 | Sponsor presentation |
Miltenyi Biotec
|
|
| 15:05 | Coffee break | ||
| Session IV Chairs: Qing-Sheng Mi (Henry Ford Health, United States), Antonia Rotolo (University of Pennsylvania, United States) |
|||
| 15:30 | Keynote lecture |
Lili Yang
University of California, United States
|
TBS
|
| 16:00 | Special guest presentation |
Iris Marchal
Associate Editor Reviews Nature Biotechnology
|
TBS
|
| 16:25 | Elevator pitch |
Naeimeh Tavakolinia
University of Melbourne, Australia
|
iNKT cells develop through a 4-stage pathway in human
|
|
Sarah Ferguson
University of Wisconsin School of Medicine and Public Health, United States
|
Analysis of iNKT-DC adjuvancy mechanisms through RNAseq
|
||
|
Li Zhou
Henry Ford Health, United States
|
Histone deacetylase 3 controls multiple key aspects of iNKT cell development
|
||
| 16:45 | Poster walk | ||
| 18:00 | Social event |
Networking in Carolinum national cultural monument – tour and reception
|
|
| DAY 3, February 15, 2025 | |||
| Session V Chairs: Tomáš Kříž (Charles University, Czech Republic), Federico Simonetta (Geneva University Hospital, Switzerland) |
|||
| 09:00 | Short talk |
Tai-Na Wu
Agricultural Biotechnology Research Center, Taiwan
|
Galactolipids inhibit Triple-Negative Breast Cancer Growth through reprogramming the tumor microenvironment
|
| 09:15 | Keynote lecture |
Marie-Thérèse Rubio
Nancy University Hospital, France
|
iNKT cells in allogeneic stem cell transplantation: from patients to the bench side
|
| 09:45 | Keynote lecture |
Anastasios Karadimitris
Imperial College London, United Kingdom
|
iNKT cell based- cell immunotherapeutics: what is the evidence?
|
| 10:15 | Coffee break | ||
| Session VI Chairs: Lucie Houdová (University of West Bohemia in Pilsen, Czech Republic), Tereza Coman (Gustave Roussy, France) |
|||
| 10:45 | Keynote lecture |
Federico Simonetta
Geneva University Hospital, Switzerland
|
iNKT cell heterogeneity: implications for cellular therapy
|
| 11:15 | Short talk |
Tereza Dekojová
University Hospital Pilsen, Czech Republic
|
iNKT for the prevention and treatment of post-transplant complications
|
| 11:30 | Short talk |
Adam Svobodník
CZECRIN, Czech Republic
|
Management of multicentric clinical studies
|
| 11:45 | Best abstracts award ceremony | ||
| 12:00 | Future directions of CiRT |
Lucie Houdová
University of West Bohemia in Pilsen, Czech RepublicCiRT co-founder |
|
| 12:20 | Lunch to go | ||